ARCUTIS BIOTHERAPEUTICS INC
ARQTNASDAQTrading Snapshot
- Day Range
- $31.38 – $32.08
- 52-Week Range
- $19.30 – $33.30
- Volume (shares)
- 1,706,630
- Avg Volume (shares)
- —
- Shares Outstanding
- 125.7M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $376M
- Last Q Revenue
- $130M
- P/E Ratio
- 139.7
- P/S Ratio
- 8.6x
- EPS (TTM)
- $0.21
- Dividend Yield
- —
- Dilution (1yr)
- +12.1%
ARCUTIS BIOTHERAPEUTICS INC
ARQT
StockOtter · stockotter.spaceAbout ARCUTIS BIOTHERAPEUTICS INC
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Appoints Rob Scott, MD to Board of Directors
Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
Arcutis today announced that it will report its Q3 2026 financial results and provide a business update after the U.S. financial markets close on Nov 4.
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,728 Shares of Company Stock
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) Director Howard Welgus sold 4,728 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales growth and expansion oppo